Overall, we suggest that the SALL2-AXIN2 axis is an essential novel component of the Wnt/β-catenin signaling pathway and a potential molecular target for reversing drug resistance in colon cancer. This evidence concerns the gene AXIN2 and malignant colon neoplasm.